Related Experiment Video
Updated: Jul 13, 2026
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement
Frederick G P Welt1, Wayne Batchelor2, J Richard Spears3
1Department of Medicine, Division of Cardiovascular Medicine, University of Utah Hospital, Salt Lake City, Utah, USA.
Insights
Myocardial ischemia-reperfusion injury, a complication of ST-elevation myocardial infarction treatment, causes further heart damage. Understanding its molecular basis aids in developing new pharmacologic and mechanical therapies to improve patient outcomes.
Area of Science:
- Cardiology
- Pathophysiology
- Biomedical Engineering
Background:
- ST-segment elevation myocardial infarction (STEMI) treatment has improved, yet patient mortality remains high.
- Reperfusion therapy, while crucial for myocardial salvage, can paradoxically exacerbate injury through ischemia-reperfusion (I-R) processes.
- Myocardial ischemia-reperfusion injury is a significant clinical challenge following acute myocardial infarction.
Purpose of the Study:
- To review the pathological and molecular mechanisms underlying myocardial ischemia-reperfusion injury.
- To explore current and emerging therapeutic strategies for mitigating I-R injury.
- To highlight the potential of both pharmacologic and mechanical interventions.
Main Methods:
- Review of existing literature on myocardial ischemia-reperfusion injury.
- Analysis of molecular pathways including reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and microvascular impairment.
- Examination of preclinical and clinical data for pharmacologic and mechanical therapeutic approaches.
Main Results:
- Pathologic and molecular bases of I-R injury are increasingly understood.
- Pharmacologic strategies have shown promise in preclinical models and some clinical settings.
- Mechanical approaches, such as cardiac unloading, are under investigation in clinical trials.
Conclusions:
- Myocardial ischemia-reperfusion injury involves complex molecular and cellular processes.
- Targeting these mechanisms offers therapeutic opportunities.
- Combined pharmacologic and mechanical strategies may represent the future of I-R injury management in STEMI.
Abstract:
Despite impressive improvements in the care of patients with ST-segment elevation myocardial infarction, mortality remains high. Reperfusion is necessary for myocardial salvage, but the abrupt return of flow sets off a cascade of injurious processes that can lead to further necrosis. This has been termed myocardial ischemia-reperfusion injury and is the subject of this review. The pathologic and molecular bases for myocardial ischemia-reperfusion injury are increasingly understood and include injury from reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and impaired microvascular flow. A variety of pharmacologic strategies have been developed that have worked well in preclinical models and some have shown promise in the clinical setting. In addition, there are newer mechanical approaches including mechanical unloading of the heart prior to reperfusion that are in current clinical trials.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management